A Phase 3 interventional study of ELGN-2112 and Placebo in Intestinal Malabsorption, sponsored by Elgan Pharma Ltd.. Recruiting at 1 site in Israel. Open to participants aged 1 Day to 5 Days. Per ClinicalTrials.gov, last updated 2026-01-23.
Sponsored by Elgan Pharma Ltd. · Phase 3, Interventional, and Treatment
The study will evaluate the effect of ELGN-2112 on intestinal malabsorption in preterm infants.
54 studies on the registry are indexed under Malabsorption Syndromes; 12 are open to participants now.
This study's planned enrollment of 360 is above the median of 38 across 44 interventional studies indexed under Malabsorption Syndromes.
Browse Malabsorption Syndromes studies →Elgan Pharma Ltd. is the lead sponsor of 5 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
-
Drug: ELGN-2112
Drug: Placebo
Human insulin \[rDNA\]
Placebo
Numbers of days to achieve full enteral feeding
Time frame: 28 days or discharge from hospital
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Elgan Pharma Ltd.